新型冠状病毒肺炎是由严重急性呼吸道综合征冠状病毒2引起的急性呼吸道传染病,是近百年来人类遭遇的影响范围最广的全球性大流行疾病。抗病毒药物是治疗新型冠状病毒感染的首选。口服小分子抗新型冠状病毒药物使用方便,且适用于轻中症患者。目前小分子抗新型冠状病毒药物有血管紧张素转换酶2(ACE2)抑制剂、膜融合抑制剂、RNA聚合酶抑制剂和3CL蛋白酶抑制剂。归纳了口服小分子抗新型冠状病毒药物的研究进展,为口服小分子抗新型冠状病毒药物的研发提供思路。

Coronavirus disease 2019 (COVID-19), which emerged in December 2019, is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection，which is the most widespread global pandemic in the past century. Antiviral drugs are the first choice for treatment of SARS-CoV-2 infection. Orally small molecule antiviral drugs against SARS-CoV-2 are convenient to use and suitable for patients with mild and moderate cases. At present, orally small molecule antiviral drugs against SARS-CoV-2 include ACE2 inhibitor, membrane fusion inhibitor, RNA polymerase inhibitor and 3CL protease inhibitor. This article focuses on research progress on orally small molecule antiviral drugs against SARS-CoV-2 to provide ideas for its drug development.

R978.7

河北省医学科学研究课题计划(20200034)